April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Tolerability, Safety and Pharmacokinetics of ONO-9054, a novel FP/EP3 dual receptor agonist: a 14 day study in subjects with ocular hypertension or open angle glacoma
Author Affiliations & Notes
  • Cheryl L Rowe-Rendleman
    Clinical, Omar Consulting Grp LLC, Princeton Junction, NJ
    Drug Development, Ono Pharma USA, Lawrenceville, NJ
  • Akifumi Fujii
    Drug Development, Ono Pharma USA, Lawrenceville, NJ
  • Takafumi Ouchi
    Drug Development, Ono Pharma USA, Lawrenceville, NJ
  • Fumitaka Suto
    Drug Development, Ono Pharma USA, Lawrenceville, NJ
  • Douglas T Ross
    Drug Development, Ono Pharma USA, Lawrenceville, NJ
  • Andrew Wood
    Drug Development, Ono Pharma USA, Lawrenceville, NJ
  • Footnotes
    Commercial Relationships Cheryl Rowe-Rendleman, Ono Pharma USA (C); Akifumi Fujii, Ono Pharma USA (E); Takafumi Ouchi, Ono Pharma USA (E); Fumitaka Suto, Ono Pharma USA (E); Douglas Ross, Ono Pharma USA (E); Andrew Wood, Ono Pharma USA (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 561. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cheryl L Rowe-Rendleman, Akifumi Fujii, Takafumi Ouchi, Fumitaka Suto, Douglas T Ross, Andrew Wood; Tolerability, Safety and Pharmacokinetics of ONO-9054, a novel FP/EP3 dual receptor agonist: a 14 day study in subjects with ocular hypertension or open angle glacoma. Invest. Ophthalmol. Vis. Sci. 2014;55(13):561.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: A randomized double masked clinical trial was performed to evaluate the safety, tolerability and pharmacokinetics (PK) of ONO-9054 a novel IOP lowering drug that targets both the prostaglandin FP and EP3 receptors in the eye.

Methods: 48 subjects with ocular hypertension or early open-angle glaucoma were recruited to 4 cohorts and randomized 1:3 to placebo or one of 4 active doses of ONO-9054 at 3, 10, 20 or 30 μg/mL. Adverse events (AEs) and tolerability were assessed during the study period from Days 1-19, and at follow up on Day 25. Blood samples taken for PK were collected by venipuncture from predose thru 6 hours post dose.

Results: Seventeen subjects had 23 AEs, of which 21 were regarded as mild and the remaining 2 as moderate. The most frequent systemic AE was headache (3/48). All ocular AEs were mild except for 2 moderate cases of anterior uveitis which could not be definitely related to the drug. After 14 days of dosing all patients were graded with no or mild hyperemia. The Cmax and AUClast of ONO-AG-367 increased approximately dose proportionally from 3.0 to 30 μg/mL but there were no signs of accumulation.

Conclusions: These data indicate that ONO-9054 is safe and well tolerated at concentrations up to 30 μg/mL. The profile of AEs is similar to that reported for currently prescribed prostaglandin analogues and the tolerability profile suggests that hyperemia may be lower. PK results indicate that neither ONO-9054 nor its active metabolite accumulate in blood and this dual agonist may become a useful tool in glaucoma medical therapy.

Keywords: 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 568 intraocular pressure • 583 lipids  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×